GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Non Operating Income

STOK (Stoke Therapeutics) Non Operating Income : $-0.41 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. Stoke Therapeutics's Non Operating Income for the three months ended in Sep. 2024 was $0.03 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.41 Mil.


Stoke Therapeutics Non Operating Income Historical Data

The historical data trend for Stoke Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Non Operating Income Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Non Operating Income
Get a 7-Day Free Trial - 0.10 0.14 0.17 0.17

Stoke Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 -0.43 -0.05 0.03

Stoke Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stoke Therapeutics Non Operating Income Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Stoke Therapeutics Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Executives
Skorpios Trust 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Barry Ticho officer: Chief Medical Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Huw M. Nash officer: COO & CBO C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Jonathan Allan officer: General Counsel & Corp Sec C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Kaye Edward M. Md director, officer: CEO 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Stephen J Tulipano officer: CFO C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Atp Life Science Ventures, L.p. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Montrago Trustees Ltd 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau officer: EVP Research & Preclinical Dev C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin director 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Arthur Tzianabos director C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730